180 Life Sciences Corporate Media Kit

4 Leadership Prof Sir Marc Feldmann Co-Chairman • Pioneer of anti-TNF therapy, world’s biggest drug class ($40B USD pa) • Anti-TNF discovery eventually led to Centocor’s acquisition by J&J for $4.9 B USD • 7 International awards for Biomedical Innovation, including Crafoord and Lasker Awards , fellow of the Royal Society Prof Lawrence Steinman Co-Chairman • Discovered role of integrins, led to Natalizumab, highly effective treatment for MS and IBD • Tysabri sold to Biogen for $3.25B • Member of National Academy of Sciences, 4 International awards for Biomedical Innovation including Charcot Prize; founder of Centocor Prof Raphael Mechoulam Founder, 180 LS • Godfather of cannabinoid chemistry; discovered the body’s endocannabinoid system • Recipient of Israel Exact Sciences Prize, member of Israel Academy of Science and Humanities Dr. James N. Woody CEO • Discovered Remicade at Centocor • Founded Avidia and Proteolix, which were sold to Amgen • GP of Latterell Venture Partners • 25+ years of pharmaceutical research and management experience • General Manager of Roche Biosciences (Former Syntex) Dr Jonathan Rothbard CSO • Stanford University, broad experience in small molecule development • Founder of 5 biotech companies; Amylin sold to AstraZeneca and BMS for $5.3B USD Prof Jagdeep Nanchahal CMO • Surgeon-scientist, leading 2b/3 trial funded by Wellcome Trust and UK Dept. of Health • Fellow of the Royal College of Surgeons; discovered new treatments for fibrosis 180 Life Sciences Corp. www.180lifesciences.com Q4 2020